Neurocrine Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M | $37.0M | $21.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | $4.0M |
| Depreciation | $26.0M | $23.5M | $17.8M | $15.1M | $10.9M | $8.6M | $7.4M | $4.0M |
| Amortization | $4.1M | $3.6M | $3.5M | $500.0K | $0 | $0 | — | — |
| Stock-Based Compensation | $217.9M | $195.5M | $194.3M | $173.1M | $134.2M | $100.0M | $75.3M | $58.1M |
| Net Cash from Operating Activities | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M | $228.5M | $147.0M | $101.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $34.0M | $38.2M | $28.3M | $16.5M | $23.4M | $10.9M | $14.7M | $24.8M |
| Business Acquisitions | — | $0 | $0 | $42.7M | $0 | $0 | — | — |
| Net Cash from Investing Activities | $-264.4M | $-126.8M | $-467.1M | $-177.1M | $-130.2M | $4.1M | $-211.1M | $-242.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $167.7M | $300.0M | $0 | $0 | — | — | — | — |
| Net Cash from Financing Activities | $-38.3M | $-486.7M | $65.3M | $-234.3M | $27.4M | $-157.8M | $32.4M | $29.5M |
| Net Change in Cash | $480.0M | $-18.1M | $-11.6M | $-73.3M | $153.7M | $74.8M | $-31.7M | $-112.0M |
| Free Cash Flow | $748.7M | $557.2M | $361.6M | $322.9M | $233.1M | $217.6M | $132.3M | $76.6M |